Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O94761

UPID:
RECQ4_HUMAN

ALTERNATIVE NAMES:
DNA helicase, RecQ-like type 4; RTS; RecQ protein-like 4

ALTERNATIVE UPACC:
O94761; A0A087WZ30; Q3Y424; Q96DW2; Q96F55

BACKGROUND:
The ATP-dependent DNA helicase Q4, with alternative names such as DNA helicase, RecQ-like type 4, RTS, and RecQ protein-like 4, is essential for DNA repair. Its function as a DNA-dependent ATPase suggests a significant role in chromosome segregation and genomic integrity.

THERAPEUTIC SIGNIFICANCE:
Linked to diseases like RAPADILINO syndrome, Baller-Gerold syndrome, and Rothmund-Thomson syndrome 2, ATP-dependent DNA helicase Q4's gene variants underline its clinical importance. Exploring this protein's function could lead to novel therapeutic approaches for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.